The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
Health and Me on MSN1d
FDA Approves Tremfya For Active Crohn's DiseaseCrohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
Tremfya is the first and only interleukin-23 inhibitor offering both subcutaneous and intravenous induction options for Crohn ...
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
New study shows that dysfunction of protective immune cells in GI tract may contribute to onset of inflammation in Crohn's disease.
A research team led by Mount Sinai has uncovered mechanisms of abnormal immune cell function that may lead to Crohn's disease ...
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
The FDA expanded the approval of guselkumab (Tremfya) to include treatment of moderately to severely active Crohn's disease, drugmaker Johnson & Johnson announced on Thursday. An interleukin (IL)-23 ...
Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback